The lifting of the US FDA’s partial clinical hold on only one clinical study – CANOVA – of AbbVie Inc./Roche’s bcl-2 inhibitor, Venclexta (venetoclax), in multiple myeloma, after changes to its design and while keeping the hold on other studies in multiple myeloma, suggests a cautious approach is being taken to further evaluation of the drug for the additional indication.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?